Evidence map›Paper›PMID 39587128›Full record

ArticleScientific reports2024

In vitro and in silico studies of a Zn(II) complex as a potential therapeutic agent for breast cancer.

Marzieh Anjomshoa, Bagher Amirheidari, Jan Janczak, Mehdi Sahihi, Yasaman Abolhassani, Alireza Farsinejad, Hamid Forootanfar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marzieh AnjomshoaDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran. anjomshoa_1014@yahoo.com.
Bagher AmirheidariDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.
Jan JanczakInstitute of Low Temperature and Structure Research, Polish Academy of Sciences, Okólna 2 Str., 50-422, Wrocław, Poland.
Mehdi SahihiUniversité Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut de Chimie de Clermont-Ferrand, F-63000, Clermont-Ferrand, France.
Yasaman AbolhassaniDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.
Alireza FarsinejadDepartment of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Hamid ForootanfarDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran. h_forootanfar@kmu.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is one of the most life-threatening diseases of women's health worldwide. This work was conducted to assess the anti-BC potency of a new Zn(II)-based complex. The Zn(II) complex coordinated to dimethoxy-substituted bipyridine was synthesized and its molecular structure was elucidated as [Zn(

Indexed as

Antineoplastic AgentsApoptosisBreast NeoplasmsCoordination ComplexesZincAnimalsCell MovementCell ProliferationComputer SimulationFemaleHumansMCF-7 CellsMiceMolecular Docking SimulationNIH 3T3 CellsReactive Oxygen SpeciesAntineoplastic AgentsCoordination ComplexesReactive Oxygen SpeciesZinc4,4′-Dimethoxy-2,2′-bipyridineAnti-metastasisApoptosisGene expressionROS generationZn(II) complex

Identifiers

PMID39587128
PMCPMC11589879

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.